Pathophysiology of hypertriglyceridemia

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1821, Issue 5, 2012, Pages 826-832

  Hassing, H C ^a   Surendran, R P ^a   Mooij, H L ^a   Stroes, E S ^a   Nieuwdorp, M ^a   Dallinga Thie, G M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Cardiovascular disease; GPIHBP1; LMF1; LPL; Triglyceride

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A5; APOLIPOPROTEIN B48; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; APOLIPOPROTEIN E2; CD36 ANTIGEN; CHYLOMICRON; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN RECEPTOR; SYNDECAN 1; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; CARDIOVASCULAR RISK; CELLULAR DISTRIBUTION; DRUG TARGETING; FAMILIAL HYPERLIPEMIA; FAT INTAKE; GENETIC DISORDER; HOMEOSTASIS; HUMAN; HYDROLYSIS; HYPERLIPOPROTEINEMIA TYPE 3; HYPERTRIGLYCERIDEMIA; INTESTINE FUNCTION; LIPID ABSORPTION; LIPID LIVER LEVEL; LIPOLYSIS; LIPOPROTEIN SYNTHESIS; LIVER CELL; LIVER CLEARANCE; LIVER FUNCTION; LOSS OF FUNCTION MUTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

APOLIPOPROTEINS; CARDIOVASCULAR DISEASES; CARRIER PROTEINS; CHYLOMICRONS; HUMANS; HYPERTRIGLYCERIDEMIA; LIPOLYSIS; LIPOPROTEIN LIPASE; LIPOPROTEINS, VLDL; LIVER; RISK FACTORS; TRIGLYCERIDES;

EID: 84859160168     PISSN: 13881981     EISSN: 18792618     Source Type: Journal    
DOI: 10.1016/j.bbalip.2011.11.010     Document Type: Review

References (59)

1. D.J. Rader, and H.H. Hobbs Disorders of lipoprotein metabolism A.S. Fauci, D.L. Kasper, D.L. Longo, E. Braunwald, S.L. Hauser, J.L. Jameson, J. Loscalzo, Harrison's Principles of Internal Medicine 2008 McGraw Hill New York 2416 2429
2. T. Twickler, G.M. Dallinga-Thie, M.J. Chapman, and J.S. Cohn Remnant lipoproteins and atherosclerosis Curr. Atheroscler. Rep. 7 2005 140 147
3. K.J. Williams Molecular processes that handle - and mishandle - dietary lipids J. Clin. Invest. 118 2008 3247 3259
4. M. Miller, N.J. Stone, C. Ballantyne, V. Bittner, M.H. Criqui, H.N. Ginsberg, A.C. Goldberg, W.J. Howard, M.S. Jacobson, P.M. Kris-Etherton, T.A. Lennie, M. Levi, T. Mazzone, and S. Pennathur Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association Circulation 123 2011 2292 2333
5. J. Iqbal, and M.M. Hussain Intestinal lipid absorption Am. J. Physiol. Endocrinol. Metab. 296 2009 E1183 E1194
6. C.L. Yen, S.J. Stone, S. Koliwad, C. Harris, and R.V. Farese Jr. Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis J. Lipid Res. 49 2008 2283 2301
7. S. Calandra, P. Tarugi, H.E. Speedy, A.F. Dean, S. Bertolini, and C.C. Shoulders Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk J. Lipid Res. 52 2011 1885 1926
8. A.B. Cefalu, P.L. Calvo, D. Noto, M. Baldi, V. Valenti, P. Lerro, F. Tramuto, A. Lezo, I. Morra, G. Cenacchi, C. Barbera, and M.R. Averna Variable phenotypic expression of chylomicron retention disease in a kindred carrying a mutation of the Sara2 gene Metab. Clin. Exp. 59 2010 463 467
9. B. Verges Abnormal hepatic apolipoprotein B metabolism in type 2 diabetes Atherosclerosis 211 2010 353 360
10. G.M. Dallinga-Thie, A. van Tol, H. Hattori, L.C. van Vark-van, H. der Zee, and E.J. Sijbrands Jansen Plasma apolipoprotein A5 and triglycerides in type 2 diabetes Diabetologia 49 2006 1505 1511
11. G.M. Dallinga-Thie, P. Berk II, A.H. Bootsma, and H. Jansen Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides Diabetes Care 27 2004 1358 1364
12. K. Aalto-Setala, E.A. Fisher, X. Chen, T. Chajek-Shaul, T. Hayek, R. Zechner, A. Walsh, R. Ramakrishnan, H.N. Ginsberg, and J.L. Breslow Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles J. Clin. Invest. 90 1992 1889 1900
13. J. Jaeken Congenital disorders of glycosylation Ann. N. Y. Acad. Sci. 1214 2010 190 198
14. T.M. Teslovich, K. Musunuru, A.V. Smith, A.C. Edmondson, I.M. Stylianou, M. Koseki, J.P. Pirruccello, S. Ripatti, D.I. Chasman, C.J. Willer, C.T. Johansen, S.W. Fouchier, A. Isaacs, G.M. Peloso, M. Barbalic, S.L. Ricketts, J.C. Bis, Y.S. Aulchenko, G. Thorleifsson, M.F. Feitosa, J. Chambers, M. Orho-Melander, O. Melander, T. Johnson, X. Li, X. Guo, M. Li, Y. Shin Cho, M. Jin Go, Y. Jin Kim, J.Y. Lee, T. Park, K. Kim, X. Sim, R. Twee-Hee Ong, D.C. Croteau-Chonka, L.A. Lange, J.D. Smith, K. Song, J. Hua Zhao, X. Yuan, J. Luan, C. Lamina, A. Ziegler, W. Zhang, R.Y. Zee, A.F. Wright, J.C. Witteman, J.F. Wilson, G. Willemsen, H.E. Wichmann, J.B. Whitfield, D.M. Waterworth, N.J. Wareham, G. Waeber, P. Vollenweider, B.F. Voight, V. Vitart, A.G. Uitterlinden, M. Uda, J. Tuomilehto, J.R. Thompson, T. Tanaka, I. Surakka, H.M. Stringham, T.D. Spector, N. Soranzo, J.H. Smit, J. Sinisalo, K. Silander, E.J. Sijbrands, A. Scuteri, J. Scott, D. Schlessinger, S. Sanna, V. Salomaa, J. Saharinen, C. Sabatti, A. Ruokonen, I. Rudan, L.M. Rose, R. Roberts, M. Rieder, B.M. Psaty, P.P. Pramstaller, I. Pichler, M. Perola, B.W. Penninx, N.L. Pedersen, C. Pattaro, A.N. Parker, G. Pare, B.A. Oostra, C.J. O'Donnell, M.S. Nieminen, D.A. Nickerson, G.W. Montgomery, T. Meitinger, R. McPherson, M.I. McCarthy, W. McArdle, D. Masson, N.G. Martin, F. Marroni, M. Mangino, P.K. Magnusson, G. Lucas, R. Luben, R.J. Loos, M.L. Lokki, G. Lettre, C. Langenberg, L.J. Launer, E.G. Lakatta, R. Laaksonen, K.O. Kyvik, F. Kronenberg, I.R. Konig, K.T. Khaw, J. Kaprio, L.M. Kaplan, A. Johansson, M.R. Jarvelin, A.C. Janssens, E. Ingelsson, W. Igl, G. Kees Hovingh, J.J. Hottenga, A. Hofman, A.A. Hicks, C. Hengstenberg, I.M. Heid, C. Hayward, A.S. Havulinna, N.D. Hastie, T.B. Harris, T. Haritunians, A.S. Hall, U. Gyllensten, C. Guiducci, L.C. Groop, E. Gonzalez, C. Gieger, N.B. Freimer, L. Ferrucci, J. Erdmann, P. Elliott, K.G. Ejebe, A. Doring, A.F. Dominiczak, S. Demissie, P. Deloukas, E.J. de Geus, U. de Faire, G. Crawford, F.S. Collins, Y.D. Chen, M.J. Caulfield, H. Campbell, N.P. Burtt, L.L. Bonnycastle, D.I. Boomsma, S.M. Boekholdt, R.N. Bergman, I. Barroso, S. Bandinelli, C.M. Ballantyne, T.L. Assimes, T. Quertermous, D. Altshuler, M. Seielstad, T.Y. Wong, E.S. Tai, A.B. Feranil, C.W. Kuzawa, L.S. Adair, H.A. Taylor Jr., I.B. Borecki, S.B. Gabriel, J.G. Wilson, H. Holm, U. Thorsteinsdottir, V. Gudnason, R.M. Krauss, K.L. Mohlke, J.M. Ordovas, P.B. Munroe, J.S. Kooner, A.R. Tall, R.A. Hegele, J.J. Kastelein, E.E. Schadt, J.I. Rotter, E. Boerwinkle, D.P. Strachan, V. Mooser, K. Stefansson, M.P. Reilly, N.J. Samani, H. Schunkert, L.A. Cupples, M.S. Sandhu, P.M. Ridker, D.J. Rader, C.M. van Duijn, L. Peltonen, G.R. Abecasis, M. Boehnke, and S. Kathiresan Biological, clinical and population relevance of 95 loci for blood lipids Nature 466 2010 707 713
15. S.K. Nilsson, J. Heeren, G. Olivecrona, and M. Merkel Apolipoprotein A-V; a potent triglyceride reducer Atherosclerosis 219 2011 15 21
16. M. Merkel, B. Loeffler, M. Kluger, N. Fabig, G. Geppert, L.A. Pennacchio, A. Laatsch, and J. Heeren Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase J. Biol. Chem. 280 2005 21553 21560
17. X. Shu, L. Nelbach, R.O. Ryan, and T.M. Forte Apolipoprotein A-V associates with intrahepatic lipid droplets and influences triglyceride accumulation Biochim. Biophys. Acta 1801 2010 605 608
18. E.A. Fisher, N.A. Khanna, and R.S. McLeod Ubiquitination regulates the assembly of VLDL in HepG2 cells and is the committing step of the apoB-100 ERAD pathway J. Lipid Res. 52 2011 1170 1180
19. M.R. Taskinen Diabetic dyslipidemia Atheroscler. Suppl. 3 2002 47 51
20. M. Adiels, S.O. Olofsson, M.R. Taskinen, and J. Boren Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome Arterioscler. Thromb. Vasc. Biol. 28 2008 1225 1236
21. M. Peterfy, O. Ben-Zeev, H.Z. Mao, D. Weissglas-Volkov, B.E. Aouizerat, C.R. Pullinger, P.H. Frost, J.P. Kane, M.J. Malloy, K. Reue, P. Pajukanta, and M.H. Doolittle Mutations in LMF1 cause combined lipase deficiency and severe hypertriglyceridemia Nat. Genet. 39 2007 1483 1487
22. A.P. Beigneux, B.S. Davies, P. Gin, M.M. Weinstein, E. Farber, X. Qiao, F. Peale, S. Bunting, R.L. Walzem, J.S. Wong, W.S. Blaner, Z.M. Ding, K. Melford, N. Wongsiriroj, X. Shu, F. de Sauvage, R.O. Ryan, L.G. Fong, A. Bensadoun, and S.G. Young Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons Cell Metab. 5 2007 279 291
23. G.M. Dallinga-Thie, R. Franssen, H.L. Mooij, M.E. Visser, H.C. Hassing, F. Peelman, J.J. Kastelein, M. Peterfy, and M. Nieuwdorp The metabolism of triglyceride-rich lipoproteins revisited: new players, new insight Atherosclerosis 211 2010 1 8
24. S.G. Young, B.S. Davies, C.V. Voss, P. Gin, M.M. Weinstein, P. Tontonoz, K. Reue, A. Bensadoun, L.G. Fong, and A.P. Beigneux GPIHBP1, an endothelial cell transporter for lipoprotein lipase J. Lipid Res. 52 2011 1869 1884
25. K. Simons, and M.J. Gerl Revitalizing membrane rafts: new tools and insights Nat. Rev. Mol. Cell Biol. 11 2010 688 699
26. M.M. Weinstein, L. Yin, A.P. Beigneux, B.S. Davies, P. Gin, K. Estrada, K. Melford, J.R. Bishop, J.D. Esko, G.M. Dallinga-Thie, L.G. Fong, A. Bensadoun, and S.G. Young Abnormal patterns of lipoprotein lipase release into the plasma in GPIHBP1-deficient mice J. Biol. Chem. 283 2008 34511 34518
27. J.J. Rios, S. Shastry, J. Jasso, N. Hauser, A. Garg, A. Bensadoun, J.C. Cohen, and H.H. Hobbs Deletion of GPIHBP1 causing severe chylomicronemia J. Inherit. Metab. Dis. 2011 10.1007/s10545-011-9406-5
28. B.S. Davies, A.P. Beigneux, R.H. Barnes II, Y. Tu, P. Gin, M.M. Weinstein, C. Nobumori, R. Nyren, I. Goldberg, G. Olivecrona, A. Bensadoun, S.G. Young, and L.G. Fong GPIHBP1 is responsible for the entry of lipoprotein lipase into capillaries Cell Metab. 12 2010 42 52
29. W.K. Sonnenburg, D. Yu, E.C. Lee, W. Xiong, G. Gololobov, B. Key, J. Gay, N. Wilganowski, Y. Hu, S. Zhao, M. Schneider, Z.M. Ding, B.P. Zambrowicz, G. Landes, D.R. Powell, and U. Desai GPIHBP1 stabilizes lipoprotein lipase and prevents its inhibition by angiopoietin-like 3 and angiopoietin-like 4 J. Lipid Res. 50 2009 2421 2429
30. T.I. Pollin, C.M. Damcott, H. Shen, S.H. Ott, J. Shelton, R.B. Horenstein, W. Post, J.C. McLenithan, L.F. Bielak, P.A. Peyser, B.D. Mitchell, M. Miller, J.R. O'Connell, and A.R. Shuldiner A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection Science 322 2008 1702 1705
31. P. Gin, A.P. Beigneux, C. Voss, B.S. Davies, J.A. Beckstead, R.O. Ryan, A. Bensadoun, L.G. Fong, and S.G. Young Binding preferences for GPIHBP1, a glycosylphosphatidylinositol-anchored protein of capillary endothelial cells Arterioscler. Thromb. Vasc. Biol. 31 2011 176 182
32. J. Wang, M.R. Ban, B.A. Kennedy, S. Anand, S. Yusuf, M.W. Huff, R.L. Pollex, and R.A. Hegele APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia Nat. Clin. Pract. Cardiovasc. Med. 5 2008 730 737
33. R.J. Havel, and R.L. Hamilton Hepatic catabolism of remnant lipoproteins: where the action is Arterioscler. Thromb. Vasc. Biol. 24 2004 213 215
34. J.R. Bishop, M. Schuksz, and J.D. Esko Heparan sulphate proteoglycans fine-tune mammalian physiology Nature 446 2007 1030 1037
35. R.W. Mahley, D.Y. Hui, T.L. Innerarity, and U. Beisiegel Chylomicron remnant metabolism. Role of hepatic lipoprotein receptors in mediating uptake Arteriosclerosis 9 1989 I14 I18
36. R.W. Mahley, and Z.S. Ji Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E J. Lipid Res. 40 1999 1 16
37. T. Kita, M.S. Brown, D.W. Bilheimer, and J.L. Goldstein Delayed clearance of very low density and intermediate density lipoproteins with enhanced conversion to low density lipoprotein in WHHL rabbits Proc. Natl. Acad. Sci. U. S. A. 79 1982 5693 5697
38. D.C. Rubinsztein, J.C. Cohen, G.M. Berger, D.R. van der Westhuyzen, G.A. Coetzee, and W. Gevers Chylomicron remnant clearance from the plasma is normal in familial hypercholesterolemic homozygotes with defined receptor defects J. Clin. Invest. 86 1990 1306 1312
39. U. Beisiegel, W. Weber, G. Ihrke, J. Herz, and K.K. Stanley The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein Nature 341 1989 162 164
40. A. Rohlmann, M. Gotthardt, R.E. Hammer, and J. Herz Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants J. Clin. Invest. 101 1998 689 695
41. R.W. Mahley, and Y. Huang Atherogenic remnant lipoproteins: role for proteoglycans in trapping, transferring, and internalizing J. Clin. Invest. 117 2007 94 98
42. Z.S. Ji, D.A. Sanan, and R.W. Mahley Intravenous heparinase inhibits remnant lipoprotein clearance from the plasma and uptake by the liver: in vivo role of heparan sulfate proteoglycans J. Lipid Res. 36 1995 583 592
43. K.I. Stanford, J.R. Bishop, E.M. Foley, J.C. Gonzales, I.R. Niesman, J.L. Witztum, and J.D. Esko Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice J. Clin. Invest. 119 2009 3236 3245
44. I.V. Fuki, K.M. Kuhn, I.R. Lomazov, V.L. Rothman, G.P. Tuszynski, R.V. Iozzo, T.L. Swenson, E.A. Fisher, and K.J. Williams The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro J. Clin. Invest. 100 1997 1611 1622
45. E.M. Foley, and J.D. Esko Hepatic heparan sulfate proteoglycans and endocytic clearance of triglyceride-rich lipoproteins Prog. Mol. Biol. Transl. Sci. 93 2010 213 233
46. J.R. Bishop, E. Foley, R. Lawrence, and J.D. Esko Insulin-dependent diabetes mellitus in mice does not alter liver heparan sulfate J. Biol. Chem. 285 2010 14658 14662
47. J.M. MacArthur, J.R. Bishop, K.I. Stanford, L. Wang, A. Bensadoun, J.L. Witztum, and J.D. Esko Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members J. Clin. Invest. 117 2007 153 164
48. K.I. Stanford, L. Wang, J. Castagnola, D. Song, J.R. Bishop, J.R. Brown, R. Lawrence, X. Bai, H. Habuchi, M. Tanaka, W.V. Cardoso, K. Kimata, and J.D. Esko Heparan sulfate 2-O-sulfotransferase is required for triglyceride-rich lipoprotein clearance J. Biol. Chem. 285 2010 286 294
49. I.J. Goldberg, Y. Hu, H.L. Noh, J. Wei, L.A. Huggins, M.G. Rackmill, H. Hamai, B.N. Reid, W.S. Blaner, and L.S. Huang Decreased lipoprotein clearance is responsible for increased cholesterol in LDL receptor knockout mice with streptozotocin-induced diabetes Diabetes 57 2008 1674 1682
50. M. Morimoto-Tomita, K. Uchimura, Z. Werb, S. Hemmerich, and S.D. Rosen Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans J. Biol. Chem. 277 2002 49175 49185
51. K. Chen, M.L. Liu, L. Schaffer, M. Li, G. Boden, X. Wu, and K.J. Williams Type 2 diabetes in mice induces hepatic overexpression of sulfatase 2, a novel factor that suppresses uptake of remnant lipoproteins Hepatology 52 2010 1957 1967
52. D. Planer, S. Metzger, E. Zcharia, I.D. Wexler, I. Vlodavsky, and T. Chajek-Shaul Role of heparanase on hepatic uptake of intestinal derived lipoprotein and fatty streak formation in mice PLoS One 6 2011 e18370
53. E. Suviolahti, H.E. Lilja, and P. Pajukanta Unraveling the complex genetics of familial combined hyperlipidemia Ann. Med. 38 2006 337 351
54. S.D. Horswell, H.E. Ringham, and C.C. Shoulders New technologies for delineating and characterizing the lipid exome: prospects for understanding familial combined hyperlipidemia J. Lipid Res. 50 Suppl 2009 S370 S375
55. A.S. Wierzbicki, C.A. Graham, I.S. Young, and D.P. Nicholls Familial combined hyperlipidaemia: under-defined and under-diagnosed? Curr. Vasc. Pharmacol. 6 2008 13 22
56. C.T. Johansen, and R.A. Hegele Genetic bases of hypertriglyceridemic phenotypes Curr. Opin. Lipidol. 22 2011 247 253
57. R.C. Turner, H. Millns, H.A. Neil, I.M. Stratton, S.E. Manley, D.R. Matthews, and R.R. Holman Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23) BMJ 316 1998 823 828
58. B.G. Nordestgaard, M. Benn, P. Schnohr, and A. Tybjaerg-Hansen Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women JAMA 298 2007 299 308
59. S.D. Proctor, D.F. Vine, and J.C. Mamo Arterial permeability and efflux of apolipoprotein B-containing lipoproteins assessed by in situ perfusion and three-dimensional quantitative confocal microscopy Arterioscler. Thromb. Vasc. Biol. 24 2004 2162 2167